Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of PRV-300 (JNJ-42915925/CNTO 3157) in patients with moderate to severe ulcerative colitis

Trial Profile

A Phase 1b Study of PRV-300 (JNJ-42915925/CNTO 3157) in patients with moderate to severe ulcerative colitis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs JNJ 42915925 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Proof of concept
  • Acronyms PULSE
  • Most Recent Events

    • 23 Oct 2018 According to Provention Bio a media release, top-line data from PULSE is expected in the second quarter of 2019.
    • 23 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to a Provention Bio media release.
    • 13 Aug 2018 According to Provention Bio a media release, this study has been initiated the first quarter 2018. Top-line data is expected to be available in the second half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top